OBESITY OBESITY ( ( Criteria, etiology, and Criteria, etiology, and management management ) ) AND AND METABOLIC SYNDROME METABOLIC SYNDROME ( ( Criteria and management Criteria and management ) ) John MF Adam John MF Adam Division of Endocrinology and Metabolism Division of Endocrinology and Metabolism Dept. of Internal Medicine, Faculty of Medicine Dept. of Internal Medicine, Faculty of Medicine Hasanuddin University Hasanuddin University Makassar Makassar
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
OBESITY OBESITY ((Criteria, etiology, and managementCriteria, etiology, and management))
ANDANDMETABOLIC SYNDROMEMETABOLIC SYNDROME((Criteria and managementCriteria and management))
John MF AdamJohn MF Adam
Division of Endocrinology and MetabolismDivision of Endocrinology and MetabolismDept. of Internal Medicine, Faculty of MedicineDept. of Internal Medicine, Faculty of MedicineHasanuddin UniversityHasanuddin University
MakassarMakassar
OBESITYOBESITYCriteria, etiology, and managementCriteria, etiology, and management
John MF AdamJohn MF Adam
Division of Endocrinology and MetabolismDivision of Endocrinology and MetabolismDept. of Internal Medicine, Faculty of MedicineDept. of Internal Medicine, Faculty of MedicineHasanuddin UniversityHasanuddin University
Makassar 2006Makassar 2006
Obesity is defined as a condition in Obesity is defined as a condition in which therewhich there is an excess of body is an excess of body fatfat.. The operational definitions of The operational definitions of obesity and overweight however obesity and overweight however are based on are based on BMIBMI which is closely which is closely correlated with body fatnesscorrelated with body fatness
In many countries in the world, the prevalence In many countries in the world, the prevalence of obesity are rapidly rising, reflecting an overall of obesity are rapidly rising, reflecting an overall increase in general fatnessincrease in general fatness
There is aThere is a “global epidemic of obesity”.“global epidemic of obesity”. WHO report launched in 1998 signifying the WHO report launched in 1998 signifying the seriousness of this problemseriousness of this problem
Sorensen TIA. Diabetes Care 2000;23 (Suppl. 2):B1-B4
EPIDEMIOLOGYEPIDEMIOLOGY
Obesity as a Risk Factor for CAD • Obesity as a Risk Factor for CAD • The Importance of Abdominal FatThe Importance of Abdominal Fat
GynGynececoidoid ObesityObesity
AndroidAndroid ObesityObesity
Sharma 2002Sharma 2002
1.1. Body Mass Index Body Mass Index
BMIBMI ==Weight in kgWeight in kg
(Height in meters)(Height in meters)22
2. Body Fat Distribution2. Body Fat Distribution Android type (central obesity = visceral obesity) Ginecoid type (perifer obesity)
MEASUREMENT of OBESITYMEASUREMENT of OBESITY
PROPOSED CLASSIFICATION of WEIGHT PROPOSED CLASSIFICATION of WEIGHT by BMI in ADULT ASIANS (WHO 2000)by BMI in ADULT ASIANS (WHO 2000)
BMI (kg/mBMI (kg/m22) ) Risk of co-morbidities Risk of co-morbidities Classification Classification
Underweight Underweight < 18.5 < 18.5 Low ( but Increased risk Low ( but Increased risk of other clinical problems) of other clinical problems)
Normal Range 18.5 – 22.9Normal Range 18.5 – 22.9 Average AverageOverweightOverweight >> 23 23 At RiskAt Risk 23 - 24.9 Increase 23 - 24.9 IncreaseObese I 25 - 29.9 ModerateObese I 25 - 29.9 ModerateObese IIObese II >> 30 30 Severe Severe
Regional Office for the Western Pacific of the World Organization, The International Regional Office for the Western Pacific of the World Organization, The International Association for the Study of Obesity, The International Obesity Task Force. The Asia-Association for the Study of Obesity, The International Obesity Task Force. The Asia-Pacific perspective: Redefining obesity and its treatment. WHO Collaborating Centre for Pacific perspective: Redefining obesity and its treatment. WHO Collaborating Centre for the epidemiology of Diabetes and Health Promotion for Noncommunicable Disease, the epidemiology of Diabetes and Health Promotion for Noncommunicable Disease, Melbourne 2000Melbourne 2000
The Asia-Pacific Perspective: Redefining Obesity and its Treatment. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Assessment Diagnosis. 2000Assessment Diagnosis. 2000
Country Obese(BMI >30 kg/m2)
Overweight (BMI 25-29,9 kg/m2)
Korea (1995)
Thailand
Malaysia
Japan
Indonesia
1,5%
4,0%
4,7% (men)7,7% (women)
<3,0%
???
20,5%
16,0%
24,3% (men)20,2% (women)
PREVALENCE of OVERWEIGHT / PREVALENCE of OVERWEIGHT / OBESITY in SOME ASIAN COUNTRIESOBESITY in SOME ASIAN COUNTRIES
Waist circumference identifies risk of Waist circumference identifies risk of CHD independent of BMICHD independent of BMI
140140
120120
100100
8080
6060
4040
2020
00
Waist C
ircum
ference
Waist C
ircum
ference
Tertiles (cm
)T
ertiles (cm)
High (High (>>81.8) 81.8) Medium (73.7-81.7) Medium (73.7-81.7)
Low (Low (<<73.6)73.6)
High High ((>>25.2)25.2)
Medium Medium (22.2-25.1)(22.2-25.1)
Low Low (>22.1)(>22.1)
Ag
e-A
dju
sted
CH
D
Ag
e-A
dju
sted
CH
D
Inci
den
ce/1
00,0
00 P
erso
n-y
ears
Inci
den
ce/1
00,0
00 P
erso
n-y
ears
BMI Tertiles (kg / mBMI Tertiles (kg / m22))
8383
7777
128128
4646
8989
110110
5555
9797
106106
IS OBESITY A DISEASEIS OBESITY A DISEASE
PROPORTION of DISEASE PROPORTION of DISEASE PREVALENCE ATTRIBUTABLE to PREVALENCE ATTRIBUTABLE to
OBESITYOBESITY
Type 2 diabetes 57%Gallbladder disease 30%Hypertension 17%Coronary heart disease 17%Osteoarthritis 14%Breast cancer 11%Uterine cancer 11%Colon cancer 11%
DiabetesHypertensionDyslipidemiaAlbuminuria
MENMEN
66
55
44
33
22
11
0022 23 24 25 26 27 28 29 30
OD
DS
RA
TIO
OD
DS
RA
TIO
BMI (kg/m2)
Risk of diabetes, hypertension, dyslipidemia or albuminuria according to selected BMI cut-off in Hong Kong Chinese
ModerateModerateRiskRisk
Relationship of BMI, cholesterol, and blood pressure to risk of ill health. The vertical lines accepted subdivisions for low, moderate, and high risk. All three
curves show a curvilinear increase with increasing level of risk factor
Bray GA, et al. Handbook of obesity, 1998Bray GA, et al. Handbook of obesity, 1998
Reduction of excess weightReduction of excess weight
Maintenance of BMIMaintenance of BMI
Blood pressureBlood pressure
Blood glucoseBlood glucose
Glycaemic control (HbA1c) Glycaemic control (HbA1c) † †† †
Other risk factorsOther risk factors
5-6 kg or 10% of initial body weight5-6 kg or 10% of initial body weight
< 23 kg/m< 23 kg/m2 † 2 †
any reductionany reduction
any reductionany reduction
any improvementany improvement
any reductionany reduction
† † For Asian populations. BMI cut-of will be higher in Pacific IslandersFor Asian populations. BMI cut-of will be higher in Pacific Islanders† † † † Haemoglobin A1cHaemoglobin A1c
WHO, Februari 2000WHO, Februari 2000
OBESITY : TREATMENT GUIDELINE FOR BMI
BMIBMI TreatmentTreatment
18.5 - 24.9
25 - 29.9 - without disease25 - 29.9 - with disease
30 - 39.9
> 40
No treatment, diet and exercise to maintain body weightHypocaloric diet and exercise to reduce body weightHypocaloric diet and exercise, anti-obesity drug
Hypocaloric diet and exercise, anti-obesity drugSurgery
Physicians guide to the management of obesity with Xenical (4)Physicians guide to the management of obesity with Xenical (4)
TREATMENT OF OBESITY TREATMENT OF OBESITY RESULTS OF RESULTS OF ORLISTATORLISTAT
JMFA 52
>> 5% weight loss 5% weight loss >> 10% weight loss 10% weight loss
Percentage of obese patients achieving weight loss of Percentage of obese patients achieving weight loss of >> 5% or 5% or >> 10% after 1 10% after 1 year of treatment with Xenical 120 mg or placebo tid plus a mildly hypocaloric year of treatment with Xenical 120 mg or placebo tid plus a mildly hypocaloric diet. diet. Sjostrom L, Rissanen A, Andersen T. Lancet 1998;352:167-72Sjostrom L, Rissanen A, Andersen T. Lancet 1998;352:167-72
8080
6060
4040
2020
00
49.2%49.2%
68.5%68.5%
17.6%17.6%
38.8%38.8%
Placebo (n=340)Placebo (n=340)Orlistat Orlistat 120 mg tid (n=343120 mg tid (n=343
P > 0.05P > 0.05
Pat
ien
t (%
)P
atie
nt
(%)
TREATMENT OF OBESITY TREATMENT OF OBESITY RESULTS OF SIBUTRAMINE RESULTS OF SIBUTRAMINE
TRIALSTRIALS
JMFA 52
STORM: Waist CircumferenceSTORM: Waist CircumferenceReduction and Maintenance Over 2 Reduction and Maintenance Over 2
James WPT, Lancet 2000;356:2119-25James WPT, Lancet 2000;356:2119-25
JMFA 53
Sudden death is more common in those Sudden death is more common in those who are naturally fat than in the slenderwho are naturally fat than in the slender
Hippocrates 410 B.C.Hippocrates 410 B.C.
Messerli et al Arch Intern Med 1987; 147: 1725 - 1728Messerli et al Arch Intern Med 1987; 147: 1725 - 1728 JMFA 4JMFA 4
METABOLIC SYNDROME METABOLIC SYNDROME
John MF Adam
Division of Endocrinology and MetabolismDept. of Internal Medicine, Faculty of MedicineHasanuddin University
Makassar
DEFINITION
Metabolic syndrome is a constellation of lipid and nonlipid risk factors of metabolic origin. This syndrome is closely linked to a generalized metabolic disorder called insulin resistance in which the normal actions of insulin are impaired
World Health Organization, 1999World Health Organization, 1999
National Cholesterol Education Program, National Cholesterol Education Program, Adult Treatment Panel III, 2001Adult Treatment Panel III, 2001
International Diabetes Federation, 2005International Diabetes Federation, 2005
CRITERIA of METABOLIC SYNDROME
JMFA 21
COMPONENTS OF THE METABOLIC SYNDROME
Glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance together with two or more of the following :
Raised arterial pressure
Raised plasma triglycerides
Central obesity
Microalbuminuria
World Health Organization, 1999
World Health Organization. Definition, diagnosis and classification of diabetes World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication. Part 1: Diagnosis and classification of diabetes mellitus and its complication. Part 1: Diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, World Health mellitus. Department of Noncommunicable Disease Surveillance, World Health Organization, Geneva 1999Organization, Geneva 1999 JMFA 22
CLINICAL IDENTIFICATION OF THE METABOLIC SYNDROME NCEP – ATP III 2001
Metabolic syndrome > 3 risk factors
Risk factor Defining level
• Abdominal obesity* (waist circumference)†
Men > 102 cm (> 40 in) Women > 88 cm (> 35 in)• Triglycerides > 150 mg/dl• High-density lipoprotein cholesterol Men < 40 mg/dl Women < 50 mg/dl• Blood pressure > 130 / > 85 mmHg• Fasting glucose > 110 mg/dl
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ill). JAMA 2001;285:2486-2497 JMFA 23
Classification BMI (kg/m2) Risk of co-morbidilities